Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
前收盘价
US$2.335
+US$0.035 · +1.52%
盘中时间采用ET。市场数据可能有所延迟。
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
日内区间
当前US$2.335
52周区间
当前US$2.335
盘中时间采用ET。市场数据可能有所延迟。
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
日内区间
当前US$2.335
52周区间
当前US$2.335
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2104.5万 USD | 1.01亿 USD | 9706.2万 USD | 1.34亿 USD | 2.07亿 USD |
| 销货成本 | 966.1万 USD | 1.86亿 USD | 884.8万 USD | — | 1.89亿 USD |
| 毛利 | 1138.4万 USD | −8538.2万 USD | 8821.4万 USD | 1.34亿 USD | 1767.8万 USD |
| 研究与开发 | 1.23亿 USD | 2.09亿 USD | 1.92亿 USD | 2.1亿 USD | 1.89亿 USD |
| 销售、一般及管理费用 | 5398.7万 USD | 5741万 USD | 5668.7万 USD | 6103.3万 USD | 5503.8万 USD |
| 营业费用 | 1.57亿 USD | 5961.5万 USD | 2.4亿 USD | 2.71亿 USD | 5503.8万 USD |
| 折旧和摊销 | 966.1万 USD | 884.1万 USD | 884.8万 USD | 847.2万 USD | 831.5万 USD |
| 营业利润 | −1.46亿 USD | −1.45亿 USD | −1.52亿 USD | −1.38亿 USD | −3736万 USD |
| 净利润 | −1.43亿 USD | −1.19亿 USD | −1.3亿 USD | −1.33亿 USD | −3632.9万 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$3.83
上涨空间 64.03%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM612.34万0.01%715.37亿 USD0.19%US$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI494.24万0.00%6893亿 USD0.03%US$340.02-3.52%
Vanguard Extended Market ETFVXF237.08万0.00%302亿 USD0.05%US$211.44-3.21%
iShares Russell 2000 Growth ETFIWO191.46万0.01%127.32亿 USD0.24%US$320.43-3.57%
Vanguard Russell 2000 ETFVTWO120.84万0.01%168亿 USD0.06%US$103.76-2.76%
Schwab U.S. Small-Cap ETFSCHA113.56万0.01%204.47亿 USD0.03%US$30.51-2.83%
iShares Micro-Cap ETFIWC65.99万0.06%10.88亿 USD0.60%US$157.87-3.19%
Vanguard Health Care ETFVHT65.1万0.00%208亿 USD0.09%US$326.69-0.40%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
iShares Micro-Cap ETFIWC
Vanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。